Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity

Case Reports in Ophthalmology

Volumn 3, Issue 1, 2012, Pages 136-141

  Mota, Ágata ^a   Carneiro, Ângela ^a,b   Breda, Jorge ^a   Rosas, Vitor ^a   Magalhães, Augusto ^a   Silva, Renato ^a,b   Falcão Reis, Fernando ^a,b  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Anti VEGF therapy; Laser photocoagulation; Ranibizumab; Retinopathy of prematurity

Indexed keywords

RANIBIZUMAB;

ARTICLE; BIRTH WEIGHT; CASE REPORT; DISEASE COURSE; EYE DISEASE; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; INTRAOCULAR HEMORRHAGE; INTRARETINAL HEMORRHAGE; LASER COAGULATION; NEWBORN; OPHTHALMOSCOPY; OUTCOME ASSESSMENT; PREMATURITY; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; RETINA NEOVASCULARIZATION; RETINOGRAPHY; RETREATMENT; RETROLENTAL FIBROPLASIA; SUBHYALOID HEMORRHAGE; SYSTEMIC DISEASE; TREATMENT OUTCOME;

EID: 84860725765     PISSN: None     EISSN: 16632699     Source Type: Journal    
DOI: 10.1159/000338623     Document Type: Article

References (15)

1. Drenser KA, Trese MT, Capone A: Aggressive posterior retinopathy of prematurity. Retina 2010;30:S37-S40.
2. Cryotherapy for Retinopathy of Prematurity Cooperative Group: Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988;106:471-479.
3. Vander JF, McNamara JA, Tasman W, Brown GC: Revised indications for early treatment of retinopathy of prematurity. Arch Ophthalmol 2005;123:406-407.
4. Mintz-Hittner HA, Kuffel RR: Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008;28:831-838.
5. Dorta P, Kychenthal A: Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Retina 2010;30:S24-S31.
6. Micieli JA, Surkont M, Smith AF: A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 2009;148:536-543.e2.
7. Mintz-Hittner HA, Best LM: Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr 2009;21:182-187.
8. Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chévez-Barrios P: Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 2008;126:1161-1163.
9. International Committee for the Classification of Retinopathy of Prematurity: The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991-999.
10. Chung EJ, Kim JH, Ahn HS, Koh HJ: Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727-1730.
11. Jang SY, Choi KS, Lee SJ: Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity. J AAPOS 2010;14:457-459.
12. Honda S, Hirabayashi H, Tsukahara Y, Negi A: Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1061-1063.
13. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmol 2007;114:855-859.
14. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmol 2007;114:2179-2182.
15. Avery RL: Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS 2012;16:2-4.